Biologics4Life completed an exclusive licensing agreement to secure rights to initial technologies for advanced bone tissue regeneration. This agreement strengthens the company’s intellectual property portfolio and is a step toward the development of its scaffold materials.
“Accomplishment of this key milestone was made possible by the commitment of our management team along with shareholder support. This achievement lays the groundwork for our 2020 and 2021 objectives: completion of manufacturing engineering and market launch,” commented Aurelien Valet, CEO.
Biologics4Life is an early stage orthobiologics company developing a range of patented biomaterials for bone regeneration. The company seeks to create a pipeline of advanced biomaterials to provide modular options for the treatment of bone voids and lesions.